Literature DB >> 25715999

The role of KCa3.1 channels in cardiac fibrosis induced by pressure overload in rats.

Li-Mei Zhao1,2, Li-Ping Wang1,3, Hui-Fang Wang4, Xiao-Zhen Ma1, Dang-Xia Zhou5, Xiu-Ling Deng6,7.   

Abstract

The intermediate-conductance Ca(2+)-activated K(+) (KCa3.1) channels play a pivotal role in the proliferation and collagen secretion of cardiac fibroblasts. However, their contribution in cardiac fibrosis remains unknown. This study was designed to investigate whether KCa3.1 channels mediate the development of cardiac fibrosis. Pressure-overloaded rats were induced by abdominal aortic constriction and treated without or with KCa3.1 blocker (TRAM-34) or angiotensin type 1 receptor blocker (losartan) for 2 weeks. Besides the increase of blood pressure, angiotensin (Ang) II level in the plasma and myocardium, left ventricle mass and hydroxyproline concentration, myocardial hypertrophy, as well as significant collagen deposition in the perivascular regions and interstitium of the myocardium were observed in pressure-overloaded rats. The expression of leukocyte differentiation antigens (CD45 and CD3), macrophage surface marker (F4/80), tumor necrosis factor alpha, and monocyte chemotactic protein-1 (MCP-1) also significantly increased. All these alterations were prevented by losartan and TRAM-34. TRAM-34 also reduced the increase of renin and angiotensinogen in the plasma and myocardium of pressure-overloaded rats. Ang II promoted the migration of monocytes through endothelial cells and the secretion of MCP-1 from human umbilical vein endothelial cells in vitro, which was inhibited by TRAM-34. In conclusion, the present study demonstrates that TRAM-34 alleviates cardiac fibrosis induced by pressure overload, which is related to its inhibitory action on KCa3.1 channels and Ang II level. Our findings indicate that the inhibition of KCa3.1 channels may represent a novel approach of preventing the progression of cardiac fibrosis, and also add to the already developing literature of promising targets for TRAM-34.

Entities:  

Keywords:  Angiotensin II; Cardiac fibrosis; Intermediate-conductance Ca2+-activated potassium channels; Migration; Monocyte

Mesh:

Substances:

Year:  2015        PMID: 25715999     DOI: 10.1007/s00424-015-1694-4

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  43 in total

Review 1.  Structural and functional characterisation of cardiac fibroblasts.

Authors:  Patrizia Camelliti; Thomas K Borg; Peter Kohl
Journal:  Cardiovasc Res       Date:  2005-01-01       Impact factor: 10.787

2.  Cell cycle-dependent expression of potassium channels and cell proliferation in rat mesenchymal stem cells from bone marrow.

Authors:  X L Deng; C P Lau; K Lai; K F Cheung; G K Lau; G R Li
Journal:  Cell Prolif       Date:  2007-10       Impact factor: 6.831

3.  Functional KCa3.1 K+ channels are required for human lung mast cell migration.

Authors:  G Cruse; S M Duffy; C E Brightling; P Bradding
Journal:  Thorax       Date:  2006-06-29       Impact factor: 9.139

4.  Monocytic fibroblast precursors mediate fibrosis in angiotensin-II-induced cardiac hypertrophy.

Authors:  Sandra B Haudek; Jizhong Cheng; Jie Du; Yanlin Wang; Jesus Hermosillo-Rodriguez; JoAnn Trial; George E Taffet; Mark L Entman
Journal:  J Mol Cell Cardiol       Date:  2010-05-19       Impact factor: 5.000

Review 5.  Role of augmented expression of intermediate-conductance Ca2+-activated K+ channels in postischaemic heart.

Authors:  Takashi Saito; Yoshimasa Fujiwara; Risako Fujiwara; Hitoshi Hasegawa; Satoshi Kibira; Hiroto Miura; Mamoru Miura
Journal:  Clin Exp Pharmacol Physiol       Date:  2002-04       Impact factor: 2.557

6.  Fluvastatin inhibits O2- and ICAM-1 levels in a rat model with aortic remodeling induced by pressure overload.

Authors:  M Katoh; Y Kurosawa; K Tanaka; A Watanabe; H Doi; H Narita
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-08       Impact factor: 4.733

7.  A possible role for complement in the pathogenesis of chronic chagasic cardiomyopathy.

Authors:  Vera Demarchi Aiello; Márcia Martins Reis; Luiz Alberto Benvenuti; Maria de Lourdes Higuchi; José Antonio Franchini Ramires; José A Halperin
Journal:  J Pathol       Date:  2002-06       Impact factor: 7.996

8.  TRAM-34 inhibits nonselective cation channels.

Authors:  Tom Schilling; Claudia Eder
Journal:  Pflugers Arch       Date:  2007-02-23       Impact factor: 3.657

9.  Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels.

Authors:  Ivica Grgic; Eva Kiss; Brajesh P Kaistha; Christoph Busch; Michael Kloss; Julia Sautter; Anja Müller; Anuradha Kaistha; Claudia Schmidt; Girija Raman; Heike Wulff; Frank Strutz; Hermann-Josef Gröne; Ralf Köhler; Joachim Hoyer
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-13       Impact factor: 11.205

10.  Blockade of KCa3.1 ameliorates renal fibrosis through the TGF-β1/Smad pathway in diabetic mice.

Authors:  Chunling Huang; Sylvie Shen; Qing Ma; Jason Chen; Anthony Gill; Carol A Pollock; Xin-Ming Chen
Journal:  Diabetes       Date:  2013-05-08       Impact factor: 9.461

View more
  11 in total

1.  Protective role of ACE2-Ang-(1-7)-Mas in myocardial fibrosis by downregulating KCa3.1 channel via ERK1/2 pathway.

Authors:  Li-Ping Wang; Su-Jing Fan; Shu-Min Li; Xiao-Jun Wang; Jun-Ling Gao; Xiu-Hong Yang
Journal:  Pflugers Arch       Date:  2016-09-03       Impact factor: 3.657

Review 2.  Critical regulation of atherosclerosis by the KCa3.1 channel and the retargeting of this therapeutic target in in-stent neoatherosclerosis.

Authors:  Yan-Rong Zhu; Xiao-Xin Jiang; Dai-Min Zhang
Journal:  J Mol Med (Berl)       Date:  2019-06-28       Impact factor: 4.599

3.  Oxidative stress promotes myocardial fibrosis by upregulating KCa3.1 channel expression in AGT-REN double transgenic hypertensive mice.

Authors:  Li-Ping Wang; Su-Jing Fan; Shu-Min Li; Xiao-Jun Wang; Jun-Ling Gao; Xiu-Hong Yang
Journal:  Pflugers Arch       Date:  2017-04-28       Impact factor: 3.657

Review 4.  Ca2+ signalling in fibroblasts and the therapeutic potential of KCa3.1 channel blockers in fibrotic diseases.

Authors:  Katy M Roach; Peter Bradding
Journal:  Br J Pharmacol       Date:  2020-02-03       Impact factor: 8.739

5.  KCa3.1 Transgene Induction in Murine Intestinal Epithelium Causes Duodenal Chyme Accumulation and Impairs Duodenal Contractility.

Authors:  Marta Sofía Valero; Mariano Ramón-Gimenez; Javier Lozano-Gerona; Pablo Delgado-Wicke; Pilar Calmarza; Aida Oliván-Viguera; Víctor López; Ángel-Luis Garcia-Otín; Salvador Valero; Esther Pueyo; Kirk L Hamilton; Hiroto Miura; Ralf Köhler
Journal:  Int J Mol Sci       Date:  2019-03-08       Impact factor: 5.923

6.  KCa3.1 Channels Promote Cardiac Fibrosis Through Mediating Inflammation and Differentiation of Monocytes Into Myofibroblasts in Angiotensin II -Treated Rats.

Authors:  Gang She; Yu-Jie Ren; Yan Wang; Meng-Chen Hou; Hui-Fang Wang; Wei Gou; Bao-Chang Lai; Ting Lei; Xiao-Jun Du; Xiu-Ling Deng
Journal:  J Am Heart Assoc       Date:  2019-01-08       Impact factor: 5.501

Review 7.  Ion Channels Orchestrate Pancreatic Ductal Adenocarcinoma Progression and Therapy.

Authors:  Verena Hofschröer; Karolina Najder; Micol Rugi; Rayhana Bouazzi; Marco Cozzolino; Annarosa Arcangeli; Gyorgy Panyi; Albrecht Schwab
Journal:  Front Pharmacol       Date:  2021-01-19       Impact factor: 5.810

8.  Blockade of KCa3.1: A novel target to treat TGF-β1 induced conjunctival fibrosis.

Authors:  Govindaraj Anumanthan; Philip J Wilson; Ratnakar Tripathi; Nathan P Hesemann; Rajiv R Mohan
Journal:  Exp Eye Res       Date:  2017-12-12       Impact factor: 3.770

9.  KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma.

Authors:  Brandon M Brown; Brandon Pressley; Heike Wulff
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

10.  Conditional KCa3.1-transgene induction in murine skin produces pruritic eczematous dermatitis with severe epidermal hyperplasia and hyperkeratosis.

Authors:  Javier Lozano-Gerona; Aida Oliván-Viguera; Pablo Delgado-Wicke; Vikrant Singh; Brandon M Brown; Elena Tapia-Casellas; Esther Pueyo; Marta Sofía Valero; Ángel-Luis Garcia-Otín; Pilar Giraldo; Edgar Abarca-Lachen; Joaquín C Surra; Jesús Osada; Kirk L Hamilton; Siba P Raychaudhuri; Miguel Marigil; Ángeles Juarranz; Heike Wulff; Hiroto Miura; Yolanda Gilaberte; Ralf Köhler
Journal:  PLoS One       Date:  2020-03-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.